Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Autoimmune diseases --- BCG vaccines --- Tumor necrosis factor. --- therapy. --- Therapeutic use. --- Cachectin --- Lymphotoxin --- TNF (Immunology) --- Cytokines --- Glycoproteins --- Growth factors --- Macrophages --- BCG immunotherapy --- Autoimmunologic diseases --- Autoimmunity --- Immunologic diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Tumor necrosis factor --- Cytokines --- Lymphotoxin-alpha --- Tumor Necrosis Factor --- Congresses --- Lymphotoxin-alpha. --- Tumor Necrosis Factor-alpha. --- -Tumor necrosis factor --- -Cachectin --- Lymphotoxin --- TNF (Immunology) --- Glycoproteins --- Growth factors --- Macrophages --- Cellular immunity --- Immune response --- Regulation --- -Congresses --- Tumor Necrosis Factor-alpha --- Cachectin-Tumor Necrosis Factor --- TNF Superfamily, Member 2 --- TNFalpha --- Cachectin --- TNF-alpha --- Tumor Necrosis Factor Ligand Superfamily Member 2 --- Cachectin Tumor Necrosis Factor --- Tumor Necrosis Factor alpha --- Certolizumab Pegol --- Adalimumab --- Infliximab --- Necrosis --- Tumor Lysis Syndrome --- Lymphotoxin-alpha3 --- Soluble Lymphotoxin-alpha --- alpha-Lymphotoxin --- TNF Superfamily, Member 1 --- TNF-beta --- Tumor Necrosis Factor Ligand Superfamily Member 1 --- Tumor Necrosis Factor-beta --- Lymphotoxin alpha --- Lymphotoxin alpha3 --- Lymphotoxin-alpha, Soluble --- Soluble Lymphotoxin alpha --- Tumor Necrosis Factor beta --- alpha Lymphotoxin --- Kankercellen. (Congres) --- Gezwellen (Kwaadaardige). (Congres) --- Cytotoxinen. (Congres) --- Antinéoplastiques. (Congrès) --- Cellules cancéreuses. (Congrès) --- Tumeurs malignes. (Congrès) --- Cytotoxines. (Congrès) --- Antineoplastische middelen. (Congres) --- Tumor necrosis factor - Congresses --- Cytokines - Congresses --- Lymphotoxin-alpha - congresses --- Tumor Necrosis Factor - congresses

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pathogenesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-alpha is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-alpha have been demonstrated in Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, suggesting a role for TNF-alpha in their pathogenesis. Although TNF-alpha plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-alpha can produce pathological changes resulting from chronic inflammation and tissue damage. This volume provides a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-alpha inhibitors – etanercept, infliximab, and adalimumab. The most recent preclinical and clinical data is presented on this topic, which should be of interest to the preclinical researcher, the clinician, and the patient who wants to learn more about these therapies.

Tumor necrosis factor --- Anti-inflammatory agents. --- Inhibitors. --- Anti-inflammatories --- Antiinflammatory agents --- Antiphlogistics --- Antipyretics --- Inflammation --- Cachectin --- Lymphotoxin --- TNF (Immunology) --- Cytokines --- Glycoproteins --- Growth factors --- Macrophages --- Immunology. --- Rheumatology. --- Dermatology. --- Toxicology. --- Gastroenterology. --- Pharmacology/Toxicology. --- Internal medicine --- Digestive organs --- Chemicals --- Medicine --- Pharmacology --- Poisoning --- Poisons --- Skin --- Connective tissues --- Joints --- Immunobiology --- Life sciences --- Serology --- Diseases --- Toxicology --- Pharmacology. --- Gastroenterology . --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Drugs --- Pharmacy --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Ligand-receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNFa. Subsequently, the major influence of TNFa on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular physiological and pathological processes they control. Therapeutic Targets of the TNF Superfamily presents the state-of-the art account on the role of TNF superfamily members in the pathogenesis and their use in current intervention of cancers and autoimmune disease. This text will be highly valuable for investigators to understand the disease processes regulated by TNF superfamily members and to develop effective therapeutics. A view into the future, inspired by the comprehensive work presented in this volume, predicts that researchers studying TNF superfamily members will continue to make rapid progress in identifying relevant components to the disease process and new therapeutic strategies to target many human diseases including cancers, autoimmune disease and others.

Tumor necrosis factor --Agonists --Therapeutic use. --- Tumor necrosis factor. --- Tumor necrosis factor --- Autoimmune Diseases --- Tumor Necrosis Factors --- Receptors, Tumor Necrosis Factor --- Neoplasms --- Inflammation --- Drug Therapy --- Immune System Diseases --- Diseases --- Intercellular Signaling Peptides and Proteins --- Pathologic Processes --- Cytokines --- Receptors, Cytokine --- Therapeutics --- Pathological Conditions, Signs and Symptoms --- Peptides --- Biological Factors --- Proteins --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Receptors, Immunologic --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Receptors, Cell Surface --- Membrane Proteins --- Microbiology & Immunology --- Biology --- Health & Biological Sciences --- Agonists --- Therapeutic use --- Therapeutic use. --- Cachectin --- Lymphotoxin --- TNF (Immunology) --- Medicine. --- Immunology. --- Biomedicine. --- Biomedicine general. --- Immunobiology --- Life sciences --- Serology --- Clinical sciences --- Medical profession --- Human biology --- Medical sciences --- Pathology --- Physicians --- Glycoproteins --- Growth factors --- Macrophages --- Biomedicine, general. --- Health Workforce

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Value of BCG and TNF in Autoimmunity provides an overview of current research and thinking related to tumor necrosis factor (TNF) induction and the use of the bacillus Calmette-Guérin (BCG) vaccine as potential treatment approaches to diverse forms of autoimmunity. BCG, commonly known as an anti-tuberculosis vaccine, is being explored in worldwide clinical trials as an approach to the treatment of certain forms of autoimmunity. The scope of research behind this therapeutic approach spans from the basic science of TNF signaling to research in diverse autoimmune disciplines, such

Autoimmunity. --- Cellular signal transduction. --- Tumor necrosis factor. --- Autoimmune diseases --- BCG vaccines --- Tumor necrosis factor --- Immune System Diseases --- Intercellular Signaling Peptides and Proteins --- Cytokines --- Immunity --- Tuberculosis Vaccines --- Immunomodulation --- Bacterial Vaccines --- Proteins --- Biological Therapy --- Peptides --- Biological Factors --- Immune System Phenomena --- Diseases --- Phenomena and Processes --- Amino Acids, Peptides, and Proteins --- Vaccines --- Therapeutics --- Chemicals and Drugs --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Biological Products --- Complex Mixtures --- Tumor Necrosis Factors --- Immunotherapy --- Autoimmune Diseases --- Autoimmunity --- BCG Vaccine --- Medicine --- Biology --- Health & Biological Sciences --- Clinical Immunology --- Microbiology & Immunology --- Therapeutic use --- Receptors. --- Etiology. --- Cellular information transduction --- Information transduction, Cellular --- Signal transduction, Cellular --- Bioenergetics --- Cellular control mechanisms --- Information theory in biology --- Autoimmunologic diseases --- Immunologic diseases --- Cachectin receptors --- Receptors, Tumor necrosis factor --- TNF receptors --- TNFRs (Tumor necrosis factor receptors) --- Tumor necrosis factor receptors --- Cell receptors --- Death receptors --- Autoallergy --- Autoantibodies